home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

August 25, 2023

It's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning!

Via InvestorPlace

Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

August 24, 2023

Gainers Electriq Power Holdings, Inc. (NYSE: ELIQ) shares jumped 130.3% to $3.3847.

Via Benzinga

Pieris Pharmaceuticals: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

Recap: Pieris Pharmaceuticals Q1 Earnings ↗

May 10, 2023

Via Benzinga

Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

May 10, 2023

Via ACCESSWIRE

Preview: Pieris Pharmaceuticals's Earnings ↗

May 09, 2023

Via Benzinga

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

August 17, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 16, 2023

Via Benzinga

Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 18, 2023

Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.

Via Benzinga

Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

March 29, 2023

Via ACCESSWIRE

Why Pieris Pharmaceuticals Shares Shooting Higher Today? ↗

July 18, 2023

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company

Via Benzinga

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

July 18, 2023

Via ACCESSWIRE

3 Doomed Biotech Stocks Destined for Disaster ↗

July 17, 2023

Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 26, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 23, 2023

Via Benzinga

Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 26, 2023

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular...

Via Benzinga

Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 23, 2023

Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.

Via Benzinga

Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 22, 2023

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...

Via Benzinga

Why Are Pieris Pharmaceuticals Shares Tanking Today ↗

June 21, 2023

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4...

Via Benzinga

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

June 21, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

June 02, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

May 22, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

May 21, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

May 04, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023

May 02, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting

April 17, 2023

Via ACCESSWIRE

Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively ↗

March 29, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 29, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 29, 2023

Via Benzinga

Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 29, 2023

Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com